Cary, N.C. – June 9, 2011 – Industry Standard Research (ISR) today announced the launch of a new and substantial research report titled “Domestic Chinese Pharmaceutical Companies: Competitor, Complementor, or Catalyst” This report profiles 18 of the largest and fastest growing domestic Chinese pharmaceutical companies by examining their corporate structure, current products, therapeutic areas of focus, R&D efforts, and financial performance. “We don’t believe we need to convince many people that the healthcare industry in China will be one of the most exciting places to be in the coming decade”, explained Andrew Schafer, President, ISR. “One can pick up any recent global industry publication and read about recent mergers, acquisitions, or co-investments with domestic Chinese healthcare companies. Many companies know they have to be a player in China, but for many of them knowing how to get started on their research is daunting.” ISR’s new report offers a start by doing the legwork and profiling the following domestic Chinese pharmaceutical companies: Harbin Pharmaceutical Group, Shineway, Beijing Tongrentang, Simcere Pharmaceutical Group, Qilu Pharmaceutical Company, Beijing Double-crane Pharmaceutical Company, Shanghai Fosun Pharmaceutical Group, Sinovac Biotech, 3SBio, Shanghai Pharmaceutical Group, North China Pharmaceutical Group, Yangtze River Pharmaceutical Group, China Resources Sanjiu Medical & Pharmaceutical Company, Guangzhou Pharmaceutical Holdings, China Buchang Pharmaceutical Group, Shandong Xinhua Pharmaceutical Company, Zhejiang Medicine Company, and American Oriental Bioengineering. The report contains over 200 pages of information and analysis. The companies profiled in this report accounted for nearly $15 billion USD in revenue in 2010 and over $1.2 billion USD in net income. Schafer goes on to state: “Our investigation into these 18 companies reveals a broad range of information. The majority of the 18 companies are publically traded and most have seen extraordinary gains over the past few years, far outpacing their general indices. Some have begun to pull-back recently, while others continue on impressive growth curves. This report will help companies better understand the current and future position of these 18 companies within the Chinese pharmaceutical industry.” About Industry Standard Research Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our syndicated and custom research offerings, please visit the company’s Web site at www.ISRreports.com or email email@example.com.